Insight & Intelligence™

Jul 31, 2012

Top Paid Women in Biopharma

GEN’s listing of the 25 highest-paid females in the industry.

Alex Philippidis

These 25 women are pulling in the big bucks. [© stefa_neve - Fotolia.com]

#10. Robin Smith

CEO, NeoStem

2011 Compensation: $3,647,772

#9. Robin L. Washington

SVP and CFO, Gilead Sciences

2011 Compensation: $4,032,193

#8. Silvia Ayyoubi

Head of Human Resources, Roche

2011 Compensation: $4,035,692

#7. Sandra Leung

General Counsel and Secretary, Bristol-Myers Squibb

2011 Compensation: $5,491,673

#6. Laura J. Schumacher

EVP, General Counsel and Secretary, Abbott Laboratories

2011 Compensation: $5,567,493

#5. Amy W. Schulman

EVP, General Counsel, President and GM, Nutrition, Pfizer

2011 Compensation: $5,764,662

#4. Beatrice Cazala

EVP Commercial Operations, Bristol-Myers Squibb

2011 Compensation: $5,941,167

#3. Naomi Kelman

Head of Novartis OTC Division, Novartis¹

2011 Compensation: $6,927,529

#2. Sherilyn S. McCoy

Vice Chairman, Executive Committee, Johnson & Johnson

2011 Compensation: $8,733,678

#1. Heather Bresch

CEO, Mylan

2011 Compensation: $9,640,486

Leave a comment by clicking the “Comments” icon below. We want to hear your thoughts!

¹Resigned from position in 2012.

This list includes only women employed at public companies. Compensation was obtained from publicly available figures published in the companies’ Definitive Proxy Statements (DEF 14A) and/or S-1 statements for initial public offerings. For executives paid in non-U.S. currencies, $USD figures are accurate as rounded off to the nearest dollar as of July 30, 2012.